vs

Side-by-side financial comparison of American Integrity Insurance Group, Inc. (AII) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

American Integrity Insurance Group, Inc. is the larger business by last-quarter revenue ($68.1M vs $35.5M, roughly 1.9× RECURSION PHARMACEUTICALS, INC.). American Integrity Insurance Group, Inc. runs the higher net margin — 30.7% vs -304.2%, a 334.9% gap on every dollar of revenue. American Integrity Insurance Group, Inc. produced more free cash flow last quarter ($133.2M vs $-47.3M).

American International Group, Inc. (AIG) is an American multinational finance and insurance corporation with operations in more than 80 countries and jurisdictions. As of 2023, AIG employed 25,200 people. The company operates through three core businesses: general insurance, life & retirement, and a standalone technology-enabled subsidiary. General Insurance includes Commercial, Personal Insurance, U.S. and International field operations. Life & Retirement includes Group Retirement, Individua...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

AII vs RXRX — Head-to-Head

Bigger by revenue
AII
AII
1.9× larger
AII
$68.1M
$35.5M
RXRX
Higher net margin
AII
AII
334.9% more per $
AII
30.7%
-304.2%
RXRX
More free cash flow
AII
AII
$180.5M more FCF
AII
$133.2M
$-47.3M
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AII
AII
RXRX
RXRX
Revenue
$68.1M
$35.5M
Net Profit
$20.9M
$-108.1M
Gross Margin
59.8%
Operating Margin
43.0%
-304.8%
Net Margin
30.7%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.58
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AII
AII
RXRX
RXRX
Q4 25
$68.1M
$35.5M
Q3 25
$62.0M
$5.2M
Q2 25
$74.5M
$19.2M
Q1 25
$71.9M
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
AII
AII
RXRX
RXRX
Q4 25
$20.9M
$-108.1M
Q3 25
$13.2M
$-162.3M
Q2 25
$27.5M
$-171.9M
Q1 25
$38.1M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
AII
AII
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
AII
AII
RXRX
RXRX
Q4 25
43.0%
-304.8%
Q3 25
30.3%
-3327.6%
Q2 25
32.3%
-916.8%
Q1 25
59.7%
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
AII
AII
RXRX
RXRX
Q4 25
30.7%
-304.2%
Q3 25
21.2%
-3135.3%
Q2 25
36.9%
-894.2%
Q1 25
53.0%
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
AII
AII
RXRX
RXRX
Q4 25
$0.58
$-0.17
Q3 25
$0.67
$-0.36
Q2 25
$1.62
$-0.41
Q1 25
$2.78
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AII
AII
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$222.0M
$743.3M
Total DebtLower is stronger
$618.0K
$9.6M
Stockholders' EquityBook value
$337.0M
$1.1B
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage
0.00×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AII
AII
RXRX
RXRX
Q4 25
$222.0M
$743.3M
Q3 25
$171.9M
$659.8M
Q2 25
$259.6M
$525.1M
Q1 25
$236.4M
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
AII
AII
RXRX
RXRX
Q4 25
$618.0K
$9.6M
Q3 25
$721.0K
$11.9M
Q2 25
$824.0K
$14.2M
Q1 25
$926.0K
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
AII
AII
RXRX
RXRX
Q4 25
$337.0M
$1.1B
Q3 25
$315.9M
$1.0B
Q2 25
$301.9M
$919.1M
Q1 25
$186.1M
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
AII
AII
RXRX
RXRX
Q4 25
$1.2B
$1.5B
Q3 25
$1.4B
$1.4B
Q2 25
$1.6B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
AII
AII
RXRX
RXRX
Q4 25
0.00×
0.01×
Q3 25
0.00×
0.01×
Q2 25
0.00×
0.02×
Q1 25
0.00×
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AII
AII
RXRX
RXRX
Operating Cash FlowLast quarter
$138.2M
$-46.1M
Free Cash FlowOCF − Capex
$133.2M
$-47.3M
FCF MarginFCF / Revenue
195.6%
-133.1%
Capex IntensityCapex / Revenue
7.4%
3.5%
Cash ConversionOCF / Net Profit
6.62×
TTM Free Cash FlowTrailing 4 quarters
$216.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AII
AII
RXRX
RXRX
Q4 25
$138.2M
$-46.1M
Q3 25
$-7.5M
$-117.4M
Q2 25
$27.4M
$-76.4M
Q1 25
$68.1M
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
AII
AII
RXRX
RXRX
Q4 25
$133.2M
$-47.3M
Q3 25
$-11.9M
$-117.6M
Q2 25
$26.9M
$-79.6M
Q1 25
$68.0M
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
AII
AII
RXRX
RXRX
Q4 25
195.6%
-133.1%
Q3 25
-19.2%
-2272.5%
Q2 25
36.1%
-413.9%
Q1 25
94.6%
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
AII
AII
RXRX
RXRX
Q4 25
7.4%
3.5%
Q3 25
7.2%
4.7%
Q2 25
0.6%
16.4%
Q1 25
0.2%
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
AII
AII
RXRX
RXRX
Q4 25
6.62×
Q3 25
-0.57×
Q2 25
1.00×
Q1 25
1.79×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons